Sign in
Stories
Sensorion Announces AGM Results
Share
AudioCure Pharma's Hearing Technology In...
BioSenic's Progress and Patent
Biotech Advancements in Hearing Loss Tre...
Gene Therapy Revolutionizes Hearing Loss...
Myonex Acquires Creapharm's Business
Perion Acquires Hivestack for DOOH Growt...
Overview
API
Sensorion, a clinical-stage biotechnology company, has announced the results of its mixed Annual General Meeting, with shareholders approving recommended resolutions. The company is focused on developing innovative therapies for hearing loss, collaborating with the Institut Pasteur for gene therapy and gene editing. Sensorion also has programs in small molecules for the treatment and prevention of hearing loss disorders.
Ask a question
How do forward-looking statements affect the perception and investment decisions in the biotechnology sector?
How might the focus on innovative therapies for hearing loss impact the healthcare industry?
What are the potential implications of Sensorion's collaboration with the Institut Pasteur for gene therapy and gene editing?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage